News

This decision provides key regulatory approval to ensure the project's long-term uranium mining activities in the future.

Data shows that all observed drug-related adverse events were either grade 1 or 2, with no higher-level (grade 3 or above) safety incidents reported. This positive safety data provides an important foundation for the subsequent clinical development of Pas-4. Typically, demonstrating controllable safety in early clinical trials is a key prerequisite for advancing to later-stage research. Investors and analysts generally prioritize the safety profile of biopharmaceutical company candidate drugs, as it directly impacts their prospects for regulatory approval and commercialization potential. The company stated that it will continue to advance Pas-4’s research programs and evaluate its therapeutic potential in the target indications.

At the same time, the institution significantly raised its target stock price from $45 to $70.